Lipopolysaccharide, immune activation, and liver abnormalities in HIV/hepatitis B virus (HBV)-coinfected individuals receiving HBV-active combination antiretroviral therapy

Journal of Infectious Diseases

Volumn 210, Issue 5, 2014, Pages 745-751

  Crane, Megan ^a,b   Avihingsanon, Anchalee ^g   Rajasuriar, Reena ^a,b,h   Velayudham, Pushparaj ^a,b   Iser, David ^a,c   Solomon, Ajantha ^a,b   Sebolao, Baotuti ^b,d   Tran, Andrew ^b,d   Spelman, Tim ^b   Matthews, Gail ^f   Cameron, Paul ^a,b,e   Tangkijvanich, Pisit ^g   Dore, Gregory J ^f   Ruxrungtham, Kiat ^g   Lewin, Sharon R ^a,b,e  

^a MONASH UNIVERSITY   (Australia)

^b BURNET INSTITUTE   (Australia)

^c ST VINCENT S HOSPITAL   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e ALFRED HOSPITAL   (Australia)

^f UNIVERSITY OF NEW SOUTH WALES   (Australia)

^g CHULALONGKORN UNIVERSITY   (Thailand)

^h UNIVERSITY OF MALAYA   (Malaysia)

Author keywords

Fibrosis; HIV HBV coinfection; Microbial translocation

Indexed keywords

ANTIRETROVIRUS AGENT; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 10; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MONOCYTE CHEMOTACTIC PROTEIN 1; SOLUBLE CD4 ANTIGEN; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CELL STIMULATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE SEVERITY; FEMALE; HEPATITIS B; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTRANSAMINASEMIA; IMMUNOSTIMULATION; IN VITRO STUDY; LIVER BIOPSY; LIVER CELL; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; PRIORITY JOURNAL;

FIBROSIS; HIV/HBV COINFECTION; MICROBIAL TRANSLOCATION;

ANTIGENS, CD14; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ANTIVIRAL AGENTS; BACTERIAL TRANSLOCATION; BIOPSY; CYTOKINES; FEMALE; HEPATITIS B, CHRONIC; HISTOCYTOCHEMISTRY; HIV INFECTIONS; HUMANS; LIPOPOLYSACCHARIDES; LIVER; MALE;

EID: 84907423836     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiu119     Document Type: Article

References (15)

1. Thio CL, Seaberg EC, Skolasky R Jr, et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 2002; 360:1921-6.
2. Weber R, Ruppik M, Rickenbach M, et al. Decreasing mortality and changing patterns of causes of death in the Swiss HIV Cohort Study. HIV Med 2012; 14:195-207.
3. Brenchley JM, Price DA, Schacker TW, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006; 12:1365-71.
4. Rajasuriar R, Booth D, Solomon A, et al. Biological determinants of immune reconstitution in HIV-infected patients receiving antiretroviral therapy: the role of interleukin 7 and interleukin 7 receptor alpha and microbial translocation. J Infect Dis 2010; 202:1254-64.
5. Avihingsanon A, Lewin SR, Kerr S, et al. Efficacy of tenofovir disoproxil fumarate/emtricitabine compared with emtricitabine alone in antiretroviral- naive HIV-HBV coinfection in Thailand. Antivir Ther 2010; 15:917-22.
6. Lo BK, Yu M, Zloty D, Cowan B, Shapiro J, McElwee KJ. CXCR3/ligands are significantly involved in the tumorigenesis of basal cell carcinomas. Am J Pathol 2010; 176:2435-46.
7. Helbig KJ, Ruszkiewicz A, Lanford RE, et al. Differential expression of the CXCR3 ligands in chronic hepatitis C virus (HCV) infection and their modulation by HCV in vitro. J Virol 2009; 83:836-46.
8. Balagopal A, Philp FH, Astemborski J, et al. Human immunodeficiency virus-related microbial translocation and progression of hepatitis C. Gastroenterology 2008; 135:226-33.
9. Garcia-Alvarez M, Berenguer J, Guzman-Fulgencio M, et al. Bacterial DNA translocation and liver disease severity among HIV infected patients with chronic hepatitis C. J Acquir Immune Defic Syndr 2012; 61:552-6.
10. Marchetti G, Nasta P, Bai F, et al. Circulating sCD14 is associated with virological response to pegylated-interferon-alpha/ribavirin treatment in HIV/HCV co-infected patients. PloS One 2012; 7:e32028.
11. Charpentier C, Champenois K, Gervais A, et al. Predictive value of liver enzymes and inflammatory biomarkers for the severity of liver fibrosis stage in HIV/HCV co-infected patients. PloS One 2013; 8:e59205.
12. Sandler NG, Koh C, Roque A, et al. Host response to translocated microbial products predicts outcomes of patients with HBV or HCV infection. Gastroenterology 2011; 141:1220-30, 30 e1-3.
13. Andrade BB, Hullsiek KH, Boulware DR, et al. Biomarkers of inflammation and coagulation are associated with mortality and hepatitis flares in persons coinfected with HIV and hepatitis viruses. J Infect Dis 2013; 207:1378-88.
14. Crane M, Oliver B, Matthews G, et al. Immunopathogenesis of hepatic flare in HIV/hepatitis B virus (HBV)-coinfected individuals after the initiation of HBV-active antiretroviral therapy. J Infect Dis 2009; 199:974-81.
15. Tan AT, Koh S, Goh W, et al. A longitudinal analysis of innate and adaptive immune profile during hepatic flares in chronic hepatitis B. J Hepatol 2010; 52:330-9.